ResearcherUniversity of TurinNo recent work listed
Massimo Aglietta
Matched on ORCID iD 0000-0002-2255-7972; OpenAlex author ID A5056702454. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 17
2013: 1 paper · 2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 3 papers · 2020: 1 paper
Papers 6
- Corrigendum to ""Shades of Gray" in pancreatic ductal adenocarcinoma: Reappraisals on resectability criteria: Debated indications for surgery in pancreatic can… Co-author DOI 10.1016/j.critrevonc.2020.102867↗
- Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan. Co-author DOI 10.1016/j.clcc.2019.08.004↗
- "Shades of Gray" in pancreatic ductal adenocarcinoma: Reappraisals on resectability criteria: Debated indications for surgery in pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2018.10.009↗
- Is There a Standard Adjuvant Therapy for Resected Pancreatic Cancer? Last author DOI 10.3390/cancers11101547↗
- A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. Co-author DOI 10.1093/annonc/mdu205↗
- Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatme… Last author DOI 10.1002/cncr.27736↗
Closest collaborators
The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Francesco Leone · 6 shared papers, 2013–2020 · strength 0.46
- Paper Corrigendum to ""Shades of Gray" in pancreatic ductal adenocarcinoma: Reappraisals on resectability criteria: Debated i… DOI 10.1016/j.critrevonc.2020.102867↗
- Paper "Shades of Gray" in pancreatic ductal adenocarcinoma: Reappraisals on resectability criteria: Debated indications for s… DOI 10.1016/j.critrevonc.2018.10.009↗
- Paper Is There a Standard Adjuvant Therapy for Resected Pancreatic Cancer? DOI 10.3390/cancers11101547↗
- Pasquale Lombardi · 4 shared papers, 2019–2020 · strength 0.39
- Paper Corrigendum to ""Shades of Gray" in pancreatic ductal adenocarcinoma: Reappraisals on resectability criteria: Debated i… DOI 10.1016/j.critrevonc.2020.102867↗
- Paper "Shades of Gray" in pancreatic ductal adenocarcinoma: Reappraisals on resectability criteria: Debated indications for s… DOI 10.1016/j.critrevonc.2018.10.009↗
- Paper Is There a Standard Adjuvant Therapy for Resected Pancreatic Cancer? DOI 10.3390/cancers11101547↗
- Elisabetta Fenocchio · 1 shared paper, 2019 · strength 0.10
- Déwi Vernerey · 1 shared paper, 2019 · strength 0.07
- Cindy Neuzillet · 1 shared paper, 2019 · strength 0.07
- Caterina Vivaldi · 1 shared paper, 2019 · strength 0.07
- Angélique Vienot · 1 shared paper, 2019 · strength 0.07
- Alessandro Passardi · 1 shared paper, 2019 · strength 0.07
- Astrid Lièvre · 1 shared paper, 2019 · strength 0.07
- Rosella Spadi · 1 shared paper, 2019 · strength 0.07
- Lorenzo Fornaro · 1 shared paper, 2019 · strength 0.07
- Francesco Montagnani · 1 shared paper, 2019 · strength 0.07
- Julien Edeline · 1 shared paper, 2019 · strength 0.07
- Enrico Vasile · 1 shared paper, 2019 · strength 0.07
- Edward Wang · 1 shared paper, 2014 · strength 0.04
- Carlo Antonio Barone · 1 shared paper, 2014 · strength 0.04
- Michael B. Sawyer · 1 shared paper, 2014 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.